Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H23N7O2 |
Molecular Weight | 345.3995 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)C=NN(CCCCN2CCN(CC2)C3=NC=CC=N3)C1=O
InChI
InChIKey=NMYAHEULKSYAPP-UHFFFAOYSA-N
InChI=1S/C16H23N7O2/c1-20-14(24)13-19-23(16(20)25)8-3-2-7-21-9-11-22(12-10-21)15-17-5-4-6-18-15/h4-6,13H,2-3,7-12H2,1H3
Molecular Formula | C16H23N7O2 |
Molecular Weight | 345.3995 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Eptapirone is a potent, selective and efficacious 5-HT1A receptor agonist. In rats, it is readily bioavailable after oral administration. Likely, because of its high efficacy at 5-HT1A receptors, Eptapirone exerted powerful antidepressant- and anxiolytic-like activity in animal models. Eptapirone given in the evening suppresses REM (rapid eye movement) sleep more than buspirone and implies a greater central effect on serotonin receptors, which is consistent with the preclinical data that indicate it has greater efficacy than buspirone. It has little effect on other sleep stages. Eptapirone has been in phase I clinical trials for the treatment of anxiety and major depressive disorder. However, this research has been discontinued.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9765347 |
8.33 null [pKi] | ||
Target ID: CHEMBL339 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9765347 |
5.75 null [pKi] | ||
Target ID: CHEMBL1907610 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9765347 |
6.16 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
1.5 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
Other AEs: Dizziness... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 1.5 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16272182
1.5 mg given in the evening
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9765347
In cells transfected with human 5-HT1A receptors, Eptapirone inhibited forskolin-induced stimulation of cAMP with a pEC50 value of 6.80.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:36:10 GMT 2023
by
admin
on
Fri Dec 15 15:36:10 GMT 2023
|
Record UNII |
3M824XRO8N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47794
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C65524
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
Eptapirone
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
7801
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
179756-85-5
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
DTXSID40170857
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
3M824XRO8N
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
C115127
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
208928
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104230
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
SUB01923MIG
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY | |||
|
100000087267
Created by
admin on Fri Dec 15 15:36:10 GMT 2023 , Edited by admin on Fri Dec 15 15:36:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|